US EditionPublished • loading... • Updated
Calidi Biotherapeutics Unveils Promising Data on CLD-401 at ASCO 2025
Summary by citybuzz.co
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Calidi Biotherapeutics Unveils Promising Data on CLD-401 at ASCO 2025
Calidi Biotherapeutics Inc. (NYSE American: CLDI), a clinical-stage biotechnology company, has unveiled promising new data on its lead candidate, CLD-401, from the RedTail platform at the American Society of Clinical Oncology (ASCO) Annual Meeting. This development marks a significant step forward in the field of systemic oncolytic targeted immunotherapies, offering new hope for patients with metastatic cancers. The company’s innovative approach…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
